UroGen Pharma (URGN) Profit After Tax (2017 - 2026)

UroGen Pharma (URGN) has 10 years of Profit After Tax data on file, last reported at -$23.6 million in Q1 2026.

• Quarterly Profit After Tax rose 46.26% year-over-year to -$23.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$133.2 million (up 3.77% YoY) and the FY2025 annual result came in at -$153.5 million, down 21.01% from the prior year.
• Profit After Tax grew to -$23.6 million in Q1 2026, from -$26.4 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$21.9 million in Q3 2023 to a low of -$49.9 million in Q2 2025.
• A 5-year average of -$30.4 million and a median of -$28.4 million in 2022 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2025 — Profit After Tax plunged 49.53% — and 2026, when it surged 46.26%.
• Tracing URGN's Profit After Tax over 5 years: stood at -$28.8 million in 2022, then grew by 9.73% to -$26.0 million in 2023, then sank by 44.19% to -$37.5 million in 2024, then advanced by 29.71% to -$26.4 million in 2025, then climbed by 10.55% to -$23.6 million in 2026.
• The last three Profit After Tax figures came in at -$23.6 million (Q1 2026), -$26.4 million (Q4 2025), and -$33.3 million (Q3 2025), per Business Quant data.